SpectraCure AB (publ)

Stockholm Stock Exchange SPEC.ST

SpectraCure AB (publ) Price to Earnings Ratio (P/E) on January 14, 2025: -12.87

SpectraCure AB (publ) Price to Earnings Ratio (P/E) is -12.87 on January 14, 2025, a 20.47% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

SpectraCure AB (publ) 52-week high Price to Earnings Ratio (P/E) is -4.94 on December 09, 2024, which is 61.60% above the current Price to Earnings Ratio (P/E).
SpectraCure AB (publ) 52-week low Price to Earnings Ratio (P/E) is -22.09 on December 16, 2024, which is -71.65% below the current Price to Earnings Ratio (P/E).
SpectraCure AB (publ) average Price to Earnings Ratio (P/E) for the last 52 weeks is -10.46.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Stockholm Stock Exchange: SPEC.ST

SpectraCure AB (publ)

CEO	Dr. Masoud Khayyami Ph.D.
IPO Date	July 1, 2015
Location	Sweden
Headquarters	Gasverksgatan 1
Employees	13
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and photo reactive drugs. It develops IDOSE software with interstitial photodynamic therapy system, which is in Phase II clinical trial for the treatment of solid tumors. The company was founded in 2003 and is based in Lund, Sweden.

Key trends

Past 5 years